Osteosarcomas in older adults: A report from the Cooperative Osteosarcoma Study Group.

Adult Chemotherapy Elderly Osteosarcoma Outcome Radiotherapy Surgery

Journal

Journal of geriatric oncology
ISSN: 1879-4076
Titre abrégé: J Geriatr Oncol
Pays: Netherlands
ID NLM: 101534770

Informations de publication

Date de publication:
04 2023
Historique:
received: 27 09 2022
revised: 16 11 2022
accepted: 30 01 2023
medline: 18 4 2023
pubmed: 27 2 2023
entrez: 26 2 2023
Statut: ppublish

Résumé

Osteosarcoma is typically a disease of the young, but may affect any age. Little is known about the disease in older patients beyond retirement age. We aim to describe the characteristics, treatment, and outcomes of older adult patients registered with our cooperative group. The database of the Cooperative Osteosarcoma Study Group (COSS) was searched for osteosarcoma patients diagnosed from 1980 to 2020 who were aged 65 years or older at diagnosis. Affected individuals were analyzed for presenting factors, treatments employed, and outcomes. Fifty-five eligible patients were detected (median age 68 [range: 65-84] years; male:female = 25:30). Among these patients, 15/55 (27%) tumors were secondary malignancies, 41/55 (75%) were high-grade central, 4/55 (7%) surface, and 10/55 (18%) extraosseous malignancies, and all but three high-grade. Primary metastases were present in 15/55 (27%) patients. Surgery was reported for 46/55 (84%) patients, radiotherapy for 6/54 (11%, 1 unknown), chemotherapy for 42/50 (84%, 5 unknown). A complete surgical remission was achieved in 31/55 (56%). There were two toxic deaths. With a median follow-up of 1.7 (range: 0.1-18.0) years for all 55 patients and 2.2 (0.1-12.4) years for 24 survivors, event-free and overall survival at 2/5 years were 39.6% (standard error: 6.8%) / 24.5% (6.5%) and 62.0% (7.1%) / 32.7% (7.5%), respectively. Tumor site, metastatic status, surgery, and a complete surgical remission were prognostic for event-free and/or overall survival. Osteosarcomas can occur in older individuals. It is more often secondary, axially located, or extraosseous than in younger patients. However, the same treatment principles seem to apply, and selected patients may be cured. Multi-center cooperation is encouraged, thereby gathering expertise for such a rare disease presentation.

Identifiants

pubmed: 36842425
pii: S1879-4068(23)00037-1
doi: 10.1016/j.jgo.2023.101445
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101445

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Auteurs

Stefan S Bielack (SS)

Cooperative Osteosarkom-Studiengruppe Gruppe COSS, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany; Klinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, Münster, Germany. Electronic address: s.bielack@klinikum-stuttgart.de.

Lars H Lindner (LH)

LMU Klinikum, Medizinische Klinik III, München, Germany.

Gerlinde Egerer (G)

Universitätsklinikum Heidelberg, Innere Medizin V: Hämatologie, Onkologie und Rheumatologie, Heidelberg, Germany.

Katrin Benzler (K)

Universitätsklinikum Tübingen; Innere Medizin II, Zentrum für Weichteilsarkome/GIST und Knochentumore, Tübingen, Germany.

Claudia Blattmann (C)

Cooperative Osteosarkom-Studiengruppe Gruppe COSS, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.

Matthias Grube (M)

Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin III, Regensburg, Germany.

Dennis Hahn (D)

Klinik für Hämatologie, Onkologie, Stammzelltransplantation und Palliativmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Katharinenhospital, Stuttgart, Germany.

Leo Kager (L)

St. Anna Kinderspital, Universitätsklinik für Kinder- und Jugendheilkunde der Medizinischen Universität Wien, and St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.

Thomas Kühne (T)

Universitäts-Kinderspital beider Basel, Abteilung für Pädiatrische Onkologie / Hämatologie, Basel, Switzerland.

Vanessa Mettmann (V)

Cooperative Osteosarkom-Studiengruppe Gruppe COSS, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.

Peter Reichardt (P)

Onkologie und Palliativmedizin, Helios Klinikum Berlin-Buch, Berlin, Germany.

Stefanie Hecker-Nolting (S)

Cooperative Osteosarkom-Studiengruppe Gruppe COSS, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Zentrum für Kinder-, Jugend- und Frauenmedizin, Stuttgart Cancer Center, Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH